211 related articles for article (PubMed ID: 28895005)
1. Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.
Niikura N; Shimomura A; Fukatsu Y; Sawaki M; Ogiya R; Yasojima H; Fujisawa T; Yamamoto M; Tsuneizumi M; Kitani A; Watanabe J; Matsui A; Takahashi Y; Takashima S; Shien T; Tamura K; Saji S; Masuda N; Tokuda Y; Iwata H
Breast Cancer Res Treat; 2018 Jan; 167(1):81-87. PubMed ID: 28895005
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
[TBL] [Abstract][Full Text] [Related]
3. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
[TBL] [Abstract][Full Text] [Related]
5. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab.
Yeo B; Kotsori K; Mohammed K; Walsh G; Smith IE
Breast; 2015 Dec; 24(6):751-7. PubMed ID: 26456898
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
Sagara Y; Takada M; Ohi Y; Ohtani S; Kurozumi S; Inoue K; Kosaka Y; Hattori M; Yamashita T; Takao S; Sato N; Iwata H; Kurosumi M; Toi M
Breast Cancer Res Treat; 2018 Oct; 171(3):675-683. PubMed ID: 29971625
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab and survival of patients with metastatic breast cancer.
Kast K; Schoffer O; Link T; Forberger A; Petzold A; Niedostatek A; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
Arch Gynecol Obstet; 2017 Aug; 296(2):303-312. PubMed ID: 28616827
[TBL] [Abstract][Full Text] [Related]
9. Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.
Bringolf L; Pestalozzi B; Fink D; Dedes K
Swiss Med Wkly; 2016; 146():w14393. PubMed ID: 28102883
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience.
Battisti NML; Tong D; Ring A; Smith I
Breast Cancer Res Treat; 2019 Nov; 178(2):401-408. PubMed ID: 31432365
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Doi T; Shitara K; Naito Y; Shimomura A; Fujiwara Y; Yonemori K; Shimizu C; Shimoi T; Kuboki Y; Matsubara N; Kitano A; Jikoh T; Lee C; Fujisaki Y; Ogitani Y; Yver A; Tamura K
Lancet Oncol; 2017 Nov; 18(11):1512-1522. PubMed ID: 29037983
[TBL] [Abstract][Full Text] [Related]
12. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
13. Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature.
Ihnenfeld Arciénega I; Imesch P; Fink D; Dedes KJ
Target Oncol; 2015 Jun; 10(2):297-301. PubMed ID: 25511015
[TBL] [Abstract][Full Text] [Related]
14. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis.
Collovà E; Ferzi A; Scandurra G; Aurilio G; Torri V; Porcu L; Sanò MV; Taibi E; Foglietta J; Generali D; Andreis D; Dazzani MC; Bramati A; Marcon I; Atzori F; Cinieri S; Tondulli L; Grasso D; Nolè F; Petrella MC; Gori S; La Verde N
Tumori; 2014; 100(4):426-31. PubMed ID: 25296592
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
17. Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?
Steenbruggen TG; Bouwer NI; Smorenburg CH; Rier HN; Jager A; Beelen K; Ten Tije AJ; de Jong PC; Drooger JC; Holterhues C; Kitzen JJEM; Levin M-; Sonke GS
Breast Cancer Res Treat; 2019 Dec; 178(3):597-605. PubMed ID: 31493033
[TBL] [Abstract][Full Text] [Related]
18. Do we really know how to overcome trastuzumab resistance in hormone sensitive metastatic breast cancer?
Cvetanovic A; Pejcic I; Zivkovic N; Krtinic D; Kostic M; Popovic L
J BUON; 2019; 24(2):516-521. PubMed ID: 31127999
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003-2015).
Daniels B; Kiely BE; Tang M; Tervonen H; Pearson SA
BMC Cancer; 2019 Sep; 19(1):909. PubMed ID: 31510955
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of S-1 plus Trastuzumab for HER2-positive Metastatic Breast Cancer (GBCCSG-01).
Fujii T; Horiguchi J; Yanagita Y; Koibuchi Y; Ikeda F; Uchida N; Kimura M;
Anticancer Res; 2018 Feb; 38(2):905-909. PubMed ID: 29374719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
